Urinary Tract Microbiota (UTM) Screening
Urinary tract microbiota (UTM) and antibiotic resistance (ABR) testing at Radeas applies modern technology to improve diagnostic speed and accuracy. Using the latest molecular techniques, pathogens and potential resistance genes can be detected with greater sensitivity and specificity than traditional culture-based methods.
Radeas delivers accurate UTM and ABR screening when turnaround time is key for high-risk patient populations or patients with complex or recurring urinary tract infections. Culture based UTI diagnostic tests take longer, favor certain pathogens over others, and are limited in their antibiotic resistance determinations. The unbiased nature of the molecular methods at Radeas ensure that the presence of one pathogen will not mask the presence of the virulent pathogen, and that the identity of potential resistance genes can be determined, not just resistance to a particular antibiotic.